Outcomes of hepatitis C‐ and hepatitis B core antibody‐positive grafts in orthotopic liver transplantation
Sammy Saab, Albert J. Chang, Scott Comulada, Sunil K. Geevarghese, R. Dean M. Anselmo, Francisco Durazo, Steven Han, Douglas G. Farmer, Hasan Yersiz, Leonard I. Goldstein, R. Mark Ghobrial, Ronald W. Busuttil – 30 December 2003 – The use of hepatitis B core antibody (HBcAb)‐ and hepatitis C virus antibody (HCV+) liver grafts for transplantation in selected populations has not affected patient and graft survival. We reexamined the clinical outcomes of using these HBcAb+ and HCV+ grafts at our institution, in addition to studying recipients of combined HBcAb+/HCV+ grafts.